Can "magic weight loss needle" really return your devil figure?

Recently, a "magical weight loss needle" is very popular in the circle of friends. Supporters have appeared in the statement saying that "one fat destroys everything, a need to solve the heart and worry", "safety and no side effects, suitable for anyone", "no diet or exercise, only once a week, you can return you a devil figure", plus plus The comparison of the body before and after the injection of the parties was exposed, it was difficult to not make people feel exciting. What is the mechanism of "fast and safe" weight loss if you do not have diet and exercise. What is the mechanism of "weight loss needle"? Is it really no safety risk?

What is the origin of the magic weight loss needle "

The "magic weight loss needle" circulating in the circle of friends is the official name of the pancreatic sugar -1 receptor agonist (GLP -1ra). This is a new type of hypoglycemic drug used in recent years. Its action mechanism is to enhance insulin secretion by activating high candy -like peptide -1 receptor in the form of glucose concentration, inhibit the secretion of pancreatic sugar, and and and of. Delaying the stomach emptiness, reducing the amount of feeding through central appetite in suppressing, thereby achieving the purpose of lowering blood sugar and weight loss.

At present, the pancreatic high sugar -like peptide -1 receptor agonist is used to treat diabetes prescription drugs. It can be used as a combined treatment drug for single medicine or multiple oral hypoglycemic drugs and basic insulin. Essence The receptor agonist that is approved to be listed on the market includes: polyethylene glycol Losna peptide, Smeglugin peptide, Licolatic peptide, Essean peptide, and du sugar peptide. Based on the blood sugar and blood lipids, these injections can achieve weight loss effect by inhibiting gastric emptying. This is why patients have decreased significantly after the needle appetite.

The 2017 Edition of the "Chinese Type 2 Diabetes Prevention Guide" takes pancreatic sugar -like peptide -1 receptor agonist as one of the two -combined treatment options after the two -meta. A number of research on cardiovascular also confirmed that some high -sugar -like peptide -1 receptor agonist has cardiac and kidney protection. Therefore, the 2020 version of "China Type 2 Diabetes Prevention Guide" recommends combined with atherosclerotic cardiovascular disease (ASCVD) Patients with type 2 diabetes with high risk of cardiovascular risk, regardless of whether the glycosylatin glycosin has reached the standard, as long as there is no contraindication, it should be used on the basis of the two -meta dual -dual -dual -dual -dual -dual -dual -cricket. Prevention. In addition, the hypoglycemic solution recommended by the Diabetes Federation Diabetes Federation in 2021 also recommends that if patients have ASCVD or have high risk of ASCVD, or heart failure, no matter what the level of glycated hemoglobin, it can be independent of the two -meta and dual -dual -dual -crickets. High sugar -like peptide -1 receptor agonist.

As a new type of hypoglycemic medicine, there are 4 advantages

For patients with diabetes, there are many benefits to the use of cigmatism -1 receptor agonist. Taking Simi Glugin as an example, the advantages of other hypoglycemic drugs are mainly manifested in 4 aspects.

1. Her sugar hypogly safety

High sugar -like peptide -1 receptor agonist is to stimulate insulin secretion through glucose dependence patterns, and reduce the secretion of pancreatic hypoglycemia. The effectiveness of blood glucose does not work normally, so as to avoid hypoglycemia caused by excessive hypoglycemic hypoglycemic.

2. Comprehensive benefits of cardiovascular metabolism

In addition to significant hypoglycemic effects, research has proved that Smeglugin peptide compared to placebo, which can reduce the risk of primary cardiovascular adverse incidents in patients with type 2 diabetes reached 26%, significantly reducing the risk of non -dead strokes to 39%. Improve patients' weight, blood pressure, blood lipids and many other indicators, and bring comprehensive benefits of cardiovascular metabolism.

3. Solid use

Smegugu peptide is a long -acting medicine that can only be administered once a week, and the design of the "injection pen" is convenient for patients to inject at home at home, and the compliance of medication will be higher.

4. Have the effect of weight loss

The weight loss effect of Smeglugin is related to suppressing appetite and delaying gastric emptying. The results of the clinical trials released by the New England Medical Journal showed that the weight loss effect brought by the drug was outstanding, and patients with obesity treatment were obese in 68 weeks of obese patients.

There are strict restrictions on losing weight for ordinary people

In recent years, the incidence of obesity in my country has risen year by year, and the situation is not optimistic. The global adult weight survey report released by "Liu Ye Dao" in 2016 shows that China's average obesity rate is 12%, and the total number of obesity has ranked first in the world.

The World Health Organization will accumulate abnormal fats that can damage healthy health and accumulate excessive fat, and define it as overweight and obesity. In short, if the heat contained in the food taken by humans exceeds the needs of the body for a long time, excess heat will be stored in the form of fat. When the stock of fat storage is significantly exceeded that the average person is normal, the weight increases and causes the weight and causes it to cause the weight and cause it to cause the weight and cause it to cause it to cause it and cause it to cause it to cause it. The abnormal changes of the body's metabolism, physiology, and biochemical.

Obesity can be divided into two types: simple and secondary. Simple obesity refers to obesity that only obese without any organic diseases, which may be related to factors such as genetic, metabolism, central nervous system's appetite regulation, endocrine function changes, and living habits such as sedentary and eclipse.

As mentioned earlier, the weight loss effect of high -sugar -like peptide -1 receptor agonist is mainly to reduce the weight by reducing energy intake and attributed to 3 points: reduce appetite, change dietary preference, and prolong the sense of satiety. So the question is: Can ordinary simple obesity of non -diabetic patients use it to reduce weight?

In June 2021, the Smeguton peptide injection was approved by the US Food and Drug Administration, which could be used for chronic weight management of obesity or overweight adults. Since then, there have been more and more people in the hospital to consult the medicine for weight loss. However, it should be noted that the application of such drugs is not as simple as "security without side effects on the Internet, suitable for anyone", "no diet or exercise, lying down to lose weight". No matter how good the medicine, there are adverse reactions, and high -glucose -like peptide -1 receptor agonist is no exception. The most common adverse reactions in the clinic include nausea, vomiting, diarrhea, constipation and indigestion, etc., and the incidence is high. Therefore, people who respond to this drug are not applicable. In fact, there are not a few people who have stopped medicine due to side effects.

For Smeglugin, the US Food and Drug Administration strictly restricts its indications for weight loss: 1. It is suitable for patients with adult group weight index (BMI) ≥30kg/m2; 2. At least one kind of weight Adult overweight groups (such as hypertension, type 2 diabetes, and high cholesterol). Therefore, doctors cannot blindly apply Smeglugin peptide to lose weight to the clinic, especially the following groups need to be cautious to use this type of drug: hypoglycemia patients, those who have suffered from pancreatitis, kidney dysfunction, thyroid marrow -like cancer or cancer Patients with multiple endocrine tumors, women during pregnancy, and patients with diabetic retinopathy. In addition, those with severe allergies for Smegutan peptide or auxiliary materials (sodium phosphate dihydrous, propylene glycol, phenol, hydrochloride, sodium hydroxide) shall be discontinued immediately and visited immediately. Patients who use oral drugs during the same period also need to know that because Smeglugin can delay gastric emptying, it may cause the body to slowly absorb oral drugs.

Weight control still follows "control your mouth and open your legs"

The basic measures for slow disease management remind us at all times that if we want to control weight, don't forget the fundamental principle of "holding your mouth and opening your legs". Losing this fundamental principle only depends on the drug after all. Moreover, at present, the dosage, use treatment, clinical weight loss effect, and adverse reactions reports of high sugar -like peptide -1 receptor agonist are basically derived from adult obesity patients with large weight. As a prescription, high -sugar -like peptide -1 receptor agonist has many precautions and adverse reactions, not a "god needle" for weight loss available for everyone. The birth of each new medicine requires time and scientific verification.

Endocrinology doctors remind everyone that high -glucose -like peptide -1 receptor agonist has not been approved by the Chinese pharmaceutical regulatory department for simply obese patients in China. Doctors are super suitable for non -diabetic patients who have weight loss demands. Using medicines or non -standard medicines, it is necessary to obtain the consent of informedness and the relevant committee of the hospital for approval. In addition, even patients in the adaptive disease should pay attention to that although the weight loss range can reach 10%-15%after use, if it is simply relying on drugs, not strictly required and actively changing their own lifestyle, then obesity Walk fast and rebound quickly.

In short, there is no shortcut to lose weight. It is difficult to last. Under the guidance of a professional physician, it is reasonable to lose weight and lose weight scientifically.

Author: Wang Shaocheng, deputy chief physician of the Department of Endocrinology, Tsinghua Chang Gung Hospital, Tsinghua University

Edit: Wang Jing

- END -